Skip to main content
PolicySpeak
← The ranking

Side by side

Compare organizations

Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.

Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

RCE
Rare Cancers Europe

Other · Switzerland

3
files engaged
of 583 tracked
3
positions filed
in those 583 files
declared FTE
self-declared
EP accreditations
as declared to the register
26
files engaged
of 583 tracked
32
positions filed
in those 583 files
7.5
declared FTE
self-declared
5
EP accreditations
as declared to the register

Declared costs: not declared · in the register since 2008

Files both filed on (3)

Medicinal products for human use · A European Health Data Space · Revision of the EU legislation on medicines for children and rare diseases

Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.

What each said, in their own words

Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.

Medicinal products for human use

Rare Cancers Europe · filed 27 Apr 2021 · source

Rare Cancers Europe (RCE), a 40-partner strong multi-stakeholder partnership, welcomes the consultation and would like to emphasise the following: 1. Ensure access: • HTA: RCE encourages the harmonisation of HTA processes and to ensure the concept of joint clinical assessments, to avoid the duplication of clinical assessments at national level, as foreseen by the draft HTA regulation.

Deutsche Sozialversicherung Europavertretung · filed 27 Apr 2021 · source

Health systems in the EU face the challenge of ensuring a high quality of affordable supply of medicines in the face of high prices. The German Social Insurance Agency therefore welcomes the EU’s intention to revise European pharmaceutical legislation.

Filed in German · English published by the European Commission

Deutsche Sozialversicherung Europavertretung · filed 2 Nov 2023 · source

The German Social Insurance Board (DSV) welcomes the Commission’s objectives of the reform proposals. They provide an opportunity to ensure equal access to medicines for patients in all Member States and to strengthen the security of supply of medicines as well as the adequacy of existing incentive schemes for drug development.

Filed in German · English published by the European Commission

A European Health Data Space

Deutsche Sozialversicherung Europavertretung · filed 2 Feb 2021 · source

The German social security umbrella organisations welcome the European Commission’s intention to shape a European health data space, in particular by: — a more binding cooperation between Member States to improve the availability and interoperability of health data with added value for patients; and — the creation of institutionalised data Governance Structure, research and development of innovation and the…

Filed in German · English published by the European Commission

Rare Cancers Europe · filed 3 Feb 2021 · source

Rare Cancers Europe (RCE), a 40-partner strong multi-stakeholder partnership, welcomes the EU efforts towards the creation of a European Health Data Space (EHDS). Rare cancers are a neglected area deserving dedicated attention as 24% of all new cancer diagnoses, including all paediatric cancers, are rare.

Revision of the EU legislation on medicines for children and rare diseases

Deutsche Sozialversicherung Europavertretung · filed 4 Jan 2021 · source

The German social security umbrella organisations in Germany welcome the plan to revise the existing incentive schemes for orphan medicinal products and paediatric medicinal products and agrees with the European Commission that the aim of this revision must be to: (1) focus support on areas where the regulations have not shown the desired success; (2) end support for areas where it is not necessary; (3) link funding…

Filed in German · English published by the European Commission

Rare Cancers Europe · filed 6 Jan 2021 · source

Rare Cancers Europe (RCE), a 39 partner strong multi-stakeholder partnership, welcomes the EU efforts to assessing solutions to improve the legislative environment on medicines for rare diseases, including rare cancers. With more than 20% of all new cancer cases being rare, including all paediatric cancers, rare cancers belong to both cancers and rare diseases.

Take this comparison with you

2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.